637031-93-7

Basic information

• Product Name: 3,3-DIFLUOROCYCLOBUTANAMINE HYDROCHLORIDE
• Synonyms: 3,3-DIFLUOROCYCLOBUTANAMINE HYDROCHLORIDE;3,3-Difluorocyclobutanami...;3,3-difluorocyclobutan-1-aMine hydrochloride;(3,3-Difluorocyclobutyl)aMine Hydrochloride;CyclobutanaMine, 3,3-difluoro-, hydrochloride (1:1);3,3-difluorocyclobutanaMine hcl;3,3-Diflurocyclobutanamine hydrochloride;3,3-Difluorocyclobutaneamine (hydrochloride)
• CAS NO: 637031-93-7
• Molecular Formula: C₄H₇F₂N*ClH
• Molecular Weight: 143.56
• EINECS: 1308068-626-2
• Product Categories: Aliphatics;Amines;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 637031-93-7.mol
• Article Data: 16

Chemical Properties

• Melting Point: 296 °C
• Boiling Point: 83.394°C at 760 mmHg
• Flash Point: -11.021°C
• Appearance: /
• Density: 1.175g/cm³
• Vapor Pressure: 75.54mmHg at 25°C
• Refractive Index: 1.405
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: Methanol (Slightly), Water (Slightly)
• CAS DataBase Reference: 3,3-DIFLUOROCYCLOBUTANAMINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,3-DIFLUOROCYCLOBUTANAMINE HYDROCHLORIDE(637031-93-7)
• EPA Substance Registry System: 3,3-DIFLUOROCYCLOBUTANAMINE HYDROCHLORIDE(637031-93-7)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 637031-93-7(Hazardous Substances Data)

Usage

Description

3,3-Difluorocyclobutanamine hydrochloride is an organic compound that serves as a key intermediate in the synthesis of various pharmaceuticals. It is characterized by its unique structure, which includes a cyclobutanamine ring with two fluorine atoms at the 3,3-positions and a hydrochloride group. 3,3-DIFLUOROCYCLOBUTANAMINE HYDROCHLORIDE is known for its potential applications in the development of antiviral and anti-cancer agents due to its ability to inhibit specific viral and cellular targets.

Uses

Used in Pharmaceutical Industry:
3,3-Difluorocyclobutanamine hydrochloride is used as a key intermediate for the preparation of piperazinyl antiviral agents. Its incorporation into these agents aids in the development of medications that can effectively combat viral infections by targeting essential viral enzymes or proteins.
Additionally, 3,3-difluorocyclobutanamine hydrochloride is used as a building block for the synthesis of kinase inhibitors. Kinases are enzymes that play a crucial role in cellular signaling pathways, and their dysregulation is often associated with various diseases, including cancer. By inhibiting these enzymes, kinase inhibitors can potentially halt the progression of diseases and offer therapeutic benefits.

InChI:InChI=1/C4H7F2N.ClH/c5-4(6)1-3(7)2-4;/h3H,1-2,7H2;1H

Upstream product

• 791061-00-2 3,3-difluorocyclobutyl-1-amine 
• 1029720-19-1 tert-butyl (3,3-difluorocyclobutyl)carbamate 
• 939399-53-8 benzyl (3,3-difluorocyclobutyl)carbamate 
• 107496-54-8 3,3-difluorocyclobutanecarboxylic acid 
• 86770-82-3 3,3-difluorocyclobutane-1-carboxamide 

Downstream Products

• 1309774-29-5 N-3,3-difluorocyclobutylcarbamic acid 4-nitro-phenyl ester 
• 1355328-30-1 N-(3,3-difluorocyclobutyl)formamide 
• 1308255-19-7 2-(5-amino-2-(N-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)sulfamoyl)phenyl)-N-(3,3-difluorocyclobutyl)acetamide 
• 1124216-77-8 3-(chloromethyl)-N-(3,3-difluorocyclobutyl)benzamide 

Relevant articles and documents

3, 3-difluorocyclobutylamine hydrochloride intermediate, synthetic method thereof and synthetic method of 3, 3-difluorocyclobutylamine hydrochloride

The invention relates to a 3, 3-difluorocyclobutylamine hydrochloride intermediate, a synthetic method thereof and a synthetic method of 3, 3-difluorocyclobutylamine hydrochloride. The method comprises the following steps: generating a methyl ester compound from 3-oxo cyclobutanecarboxylic acid under acid catalysis, fluorinating the methyl ester compound to obtain a fluoride, and reacting with hydroxylamine to generate the 3, 3-difluorocyclobutylamine hydrochloride intermediate, subjecting the 3, 3-difluorocyclobutylamine hydrochloride intermediate torearrangement reaction under the action ofsulfonyl chloride and alkali without purification and separation to obtain 3, 3-difluorocyclobutylamine, and finally salifying 3, 3-difluorocyclobutylamine and hydrochloric acid to generate 3, 3-difluorocyclobutylamine hydrochloride. The synthetic method of the 3, 3-difluorocyclobutylamine hydrochloride does not need to use azide, is mild in reaction condition, safe and environment-friendly, is simple in process route, remarkably shortens the production period, has advantages in productivity, and is simple and easily available in raw materials, low in cost and suitable for industrial mass production.

Preparation method of ivosidenib intermediate 3,3-difluorocyclobutanamine hydrochloride

The invention belongs to the technical field of medicine, and specifically relates to a preparation method of 3,3-difluorocyclobutanamine hydrochloride (I). The preparation method comprises the following steps: amidating a compound II, thus obtaining a compound III; reacting with a fluorinated reagent, thus obtaining a compound IV; then carrying out Hofman degradation reaction, thus obtaining a compound V; finally salifying, thus obtaining the 3,3-difluorocyclobutanamine hydrochloride (I). Compared with the prior art, the technical route is simple, the steps are shorter, the cost is low, the reaction condition is gentle, reagents which are toxic and are high in danger coefficient are prevented from being used, the preparation method is green and environmentally friendly, and good application value is obtained.

Lead Optimization toward Proof-of-Concept Tools for Huntington's Disease within a 4-(1 H -Pyrazol-4-yl)pyrimidine Class of Pan-JNK Inhibitors

Through medicinal chemistry lead optimization studies focused on calculated properties and guided by X-ray crystallography and computational modeling, potent pan-JNK inhibitors were identified that showed submicromolar activity in a cellular assay. Using in vitro ADME profiling data, 9t was identified as possessing favorable permeability and a low potential for efflux, but it was rapidly cleared in liver microsomal incubations. In a mouse pharmacokinetics study, compound 9t was brain-penetrant after oral dosing, but exposure was limited by high plasma clearance. Brain exposure at a level expected to support modulation of a pharmacodynamic marker in mouse was achieved when the compound was coadministered with the pan-cytochrome P450 inhibitor 1-aminobenzotriazole. (Chemical Presented)